Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 390

Futibatinib in Patients With Specific FGFR Aberrations

Futibatinib in Patients With Specific FGFR Aberrations
Conditions:   Advanced or Metastatic Solid Tumor;   Advanced or Metastatic Gastric or Gastroesophageal Cancer;   Myeloid or Lymphoid Neoplasms (MLN)
Intervention:   Drug: Futibatinib
Sponsor:   Taiho Oncology, Inc.

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 29, 2020 / by / in